Inven2 — Joint Technology-Transfer Office for University of Oslo & Oslo University Hospital

Inven2 was established in 2010 through the merger of Medinnova (Rikshospitalet's technology-transfer office), Birkeland Innovasjon and the University of Oslo's own TTO, creating a single joint vehicle owned by the University of Oslo and Oslo University Hospital. It now administers commercialisation for both owners plus all health trusts in the South-Eastern Norway Regional Health Authority, making it, by its own and independent hosts' account, one of the largest technology-transfer offices in the Nordic region.

Over its first ten years (2010–2020), Inven2 recorded 2,072 new invention disclosures, filed 260 patent applications, concluded 388 licence agreements, and helped establish 55 start-up companies. The market value of the start-ups it helped found and still partly owns grew from about NOK 500 million in 2010 to roughly NOK 15 billion in 2020 — a 30-fold increase. Inven2 reinvested NOK 582 million of licensing proceeds back into research, innovation and inventors over the same period, and by 2020 had initiated around 1,500 clinical-trial agreements, with roughly 400 clinical studies ongoing.

About two-thirds of Inven2's companies and licences sit in the life-sciences field. One notable deal — a licence with Merck for a cancer-pain drug candidate — was described by Inven2's leadership as among the most valuable licence agreements ever granted in Norway, though the specific financial terms were not disclosed. As of the mid-2020s Inven2 operates with around 32 staff spanning legal, scientific and business-development expertise.

Read the full analysis: https://www.inven2.com/about-us/?lang=en